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Autoimmune pancreatitis (AIP) is a newly recognized pancreatic disorder. Recently, International Consensus Diagnostic Criteria
for AIP (ICDC) was published. In this ICDC, AIP was classiﬁed into Type 1 and Type 2. Patients with Type 1 AIP have several
immunologic and histologic abnormalities speciﬁc to the disease, including increased levels of serum IgG4 and storiform ﬁbrosis
with inﬁltration of lymphocytes and IgG4-positive plasmacytes in the involved organs. Among the involved organs showing
extrapancreaticlesions,thebileductisthemostcommon,exhibitingsclerosingcholangitis(IgG4-SC).However,theroleofIgG4is
unclear. Recently, it has been reported that regulatory T cells (Tregs) are involved in both the development of various autoimmune
diseases and the shift of B cells toward IgG4, producing plasmacytes. Our study showed that Tregs were increased in the pancreas
with Type 1 AIP and IgG4-SC compared with control. In the patients with Type 1 AIP and IgG4-SC, the numbers of inﬁltrated
Tregs were signiﬁcantly positively correlated with IgG4-positive plasma cells. In Type 1 AIP, inducible costimulatory molecule
(ICOS)+ and IL-10+ Tregs signiﬁcantly increased compared with control groups. Our data suggest that increased quantities of
ICOS+ Tregs may inﬂuence IgG4 production via IL-10 in Type 1 AIP.
1.Introduction
In 1961, Sarles et al. observed the ﬁrst case of idiopathic
chronic pancreatitis with hypergammaglobulinemia, in
which an autoimmune mechanism was supposedly involved
[1]. In 1991, Kawaguchi et al. reported two cases of an
unusual lymphoplasmacytic sclerosing inﬂammatory disease
involvingtheentirepancreas,commonbileduct,gallbladder,
and, in one patient, the lip [2]. In addition, two patients
presented mass-like enlargement of the pancreatic head.
Histopathological characteristics included diﬀuse lympho-
plasmacytic inﬁltration, marked interstitial ﬁbrosis, acinar
atrophy, and obliterative phlebitis of the pancreatic and
portal veins, which was termed as lymphoplasmacytic scle-
rosing pancreatitis (LPSP). In 1995, Yoshida et al. ﬁrst
proposed the concept of “autoimmune pancreatitis (AIP),”
in which patients showed a diﬀusely enlarged pancreas, a
narrowing pancreatogram, increased serum IgG, the pres-
ence of autoantibodies, ﬁbrotic changes with lymphocytic
inﬁltration, and steroidal eﬃcacy [3]. In 2001, Hamano et al.
reported that elevated serum IgG4 levels were highly speciﬁc
and sensitive for the diagnosis of AIP [4]. In 2003, Kamisawa
et al. suggested that AIP is a systemic disease, based on
the ﬁndings that the pancreas and other involved organs
have abundant inﬁltration of IgG4-positive plasma cells [5].
Thereafter, Japanese investigators reported numerous AIP
cases, and AIP has been accepted as a new clinical entity
[6–9].
Human regulatory T cells (Tregs) were ﬁrst isolated from
peripheral blood and characterized as CD4+CD25high Tc e l l s2 International Journal of Rheumatology
by several groups in 2001 [10–12], based on the ﬁnding in
1995 that mouse Tregs constitutively express CD25 [13]. We
now know that these cells play a critical role in preventing
autoimmune diseases by suppressing self-reactive T cells—
whicharepresentinallhealthyindividuals—throughincom-
pletely understood mechanisms that involve cell contact and
secretion of inhibitory cytokines [14]. Although the role of
Tregs in AIP remains unclear, we will discuss Tregs and the
mechanism of IgG4 related AIP.
2. Type 1 and Type 2 AIP
Reports from Europe [15] and the United States [16]
described unique histological patterns in the resected pan-
creases of patients with mass-forming chronic nonalcoholic
pancreatitis with epithelial destruction by granulocytes,
which is now supposed to be distinguishable from Type 1
AIP, IgG4-related AIP or LPSP, and called idiopathic duct
centric pancreatitis (IDCP), AIP with granulocyte epithelial
lesions (AIP with GEL), or Type 2 AIP [17]. In 2011, the
International Consensus Diagnostic Criteria for Autoim-
mune Pancreatitis (ICDC) was published. In this ICDC, AIP
was classiﬁed into Type 1 and Type 2 [18]. Most of the
JapaneseAIPcasesareLPSP,whereasthoseconcerningIDCP
are very few. Although we recently reported the ﬁrst case of
IDCP in Japan with full radiological and histopathological
ﬁndings [19], it still remains unclear whether the clinical
manifestationsoftheJapanesepatientswithIDCParesimilar
to those of Western countries or not. Therefore, Japanese
consensus clinical guidelines have focused on Type 1 AIP
(IgG4-related AIP) [20–23]. An overlap in the histological
features of the two patterns may exist in some patients.
Although the pathogenesis is still unclear, the most impor-
tantissueinmanagingAIPistodiﬀerentiateitfrompancreas
and biliary malignancy.
3. Other Organ Involvement (OOI) in Type 1
AIP
Type 1 AIP often shows other organ involvement (OOI)
such as AIP, sclerosing cholangitis, retroperitoneal ﬁbrosis,
enlarged celiac and hilar lymph nodes, chronic thyroiditis,
and interstitial nephritis [24–28]. Moreover, sialoadenitis
is also major complication with Type 1 AIP. The patients
with Mikulicz’s disease (MD) usually have bilateral, pain-
less, and symmetrical swelling of the lachrymal, parotid,
and submandibular glands [29]. This disease is originally
classiﬁed as an atypical type of Sj¨ ogren’s syndrome. Recently,
MD has been considered to be completely diﬀerent from
Sj¨ ogren’s syndrome because of the lack of anti-SS-A/Ro
or anti-SS-B/La antibodies, elevated serum levels of IgG4,
inﬁltration of IgG4-positive plasma cells into the glands, and
recovery of secretion with steroid treatment [25]. Sclerosing
cholangitis with Type 1 AIP shows various cholangiographic
features similar to those of primary sclerosing cholangitis
(PSC). However, the steroid responses and the prognoses of
Type 1 AIP patients with sclerosing cholangitis diﬀer from
these features in patients with PSC, which suggests diﬀerent
pathogenesis. These ﬁndings led us to the concept of “IgG4-
related disease” [30] such as IgG4-related systemic sclerosing
disease [5, 31], systemic IgG4-related plasmacytic syndrome
(SIPS) [32], and IgG4-positive multiorgan lymphoprolifera-
tive syndrome (IgG4-MOLPS) [33].
4.Regulatory TCells(Tregs)
Tregs expressing the transcription factor forkhead box P3
(FOXP3) originally identiﬁed by Hori et al. have key
roles in the immune system, which are indispensable for
the maintenance of dominant self-tolerance and immune
homeostasis [34]. Dysfunction of FOXP3 is known to cause
fatal autoimmune diseases, immunopathology, and allergy
[35]. Most of FOXP3+ Tregs are CD4+ T cells strongly
expressing CD25 (the interleukin-2 (IL-2) receptor α-chain),
can suppress the activation, proliferation and eﬀector of
immune cells, including CD4+ and CD8+ T cells, natural
killer (NK) and NKT cells, B cells, and antigen-presenting
c e l l s( A P C s )i nvi t r oa n di nvi v o[ 36]. This unique ability can
make FOXP3+ Tregs to control immune responses to prevent
development of autoimmune disease, immunopathology,
and allergy, as well as to maintain allograft tolerance and
fetal-maternal tolerance during pregnancy [37].
Increased CD4+CD25+ T cells were observed in the
periphery and inﬂamed tissues of the patients with rheuma-
toid arthritis, Sj¨ ogren’s syndrome, and psoriasis, compared
with healthy controls [38]. The increased numbers of Tregs
suggest that the reason for failed regulation in the inﬂamed
tissue may be insuﬃcient or defective Tregs function due
to either cell-intrinsic or cell-extrinsic factors. However, the
precise mechanism is still unclear.
5.SubtypesofRegulatory TCells
CD4+ T-cell diﬀerentiation into the conventional T-cell and
Tregs lineages can be identiﬁed by phenotypic markers.
All T-cell lineages originate in the thymus and emigrate
as na¨ ıve CD45RA+ T cells, and activation of naive T cells
in the periphery induces their diﬀerentiation into both
conventional and regulatory subsets. Conventional T cells
further diﬀerentiate into memory T cells, which can be
reactivated. CD45RA+ na¨ ıve Tregs also diﬀerentiate into
CD45RA− eﬀector Tregs. On the other hand, the CD45RA−
peripheral Tregs compartment is converted Tregs-like cells,
whicharederivedfromconventionalTcells.Theseconverted
Tregs-like cells have cell surface marker expression similar to
that expressed by natural Tregs [39].
The eﬀector Tregs subsets are heterogeneous in the
expression of inducible costimulatory molecule (ICOS) [40].
Intheperiphery,twofunctionallydiﬀerentsubsetsofeﬀector
Tregs, ICOS+ or ICOS− eﬀector Tregs actively produce the
suppressive cytokines IL-10 or TGF-β,r e s p e c t i v e l y[ 40].
It is reported that the growth of Tregs secreting IL-10
required dendritic cells (DCs) expressing high-level ICOS-
ligand and was prevent by blockade of ICOS-ICOS-ligand
signaling [41]. DC is important in the proliferation of
ICOS+ or ICOS− Tregs. While activated plasmacytoid DCsInternational Journal of Rheumatology 3
(pDCs)preferentiallypromotetheproliferationoftheICOS+
Tregs through ICOS-ligand, activated myeloid DCs (mDCs)
preferentially promote the proliferation of the autologous
ICOS− Tregs through B7 signaling [40].
6.Tregs inType1 AIP
6.1.FlowCytometricAnalysisofPeripheralBloodinthePatient
with Type 1 AIP. To clarify the role of Tregs in IgG4-
related diseases, we analyzed Tregs showing CD4+CD25high
and CD4+CD25+CD45RA+ (na¨ ıve) from peripheral blood
by ﬂow cytometry in the patients with Type 1 AIP. For
comparison, we also analyzed patients with other pan-
creatic disease (idiopathic or alcoholic pancreatitis) and
healthy subjects as controls. In Type 1 AIP, in addition
to increased soluble CTLA4, circulatory na¨ ıve (CD45RA+)
Tregs were signiﬁcantly decreased in the peripheral blood
of the patients with AIP, whereas the major population of
eﬀector (CD45RA−) Tregs was signiﬁcantly increased [42].
In addition, we studied inﬁltrating cells in the pancreas
by immunohistochemistry and analyzed ICOS+ Tregs and
IL-10+ Tregs in the peripheral blood by ﬂow cytometry.
ICOS+ Tregs were signiﬁcantly higher in AIP patients than
in the patients with other pancreatic diseases and the healthy
control group. IL-10+ Tregs were signiﬁcantly higher in
AIP patients than in the healthy control group [43]. We
previously investigated three types of DCs: mDC (Lin-HLA-
DR+CD11c+), pDC (Lin-HLA-DR+CD11c−), and CD123+
pDC (Lin-HLA-DR+CD11c−CD123+). There were no sig-
niﬁcant diﬀerences in the three kinds of DCs among the
healthycontrol,alcoholicandidiopathicCP,andAIPgroups.
However, mDC and CD123+ pDC signiﬁcantly decreased in
patients with AIP with steroid therapy, compared with other
groups [41]. The relationship between DC and Tregs in AIP
is still unclear.
6.2. Immunohistochemical Analysis in Type 1 AIP. IgG4-
relatedsclerosingcholangitis(SC)wasrecognizedasadisease
entity characterized by sclerosing inﬂammation with abun-
dant IgG4-positive plasma cells; Type 1 AIP was associated
in most cases. We analyzed Tregs in the pancreas and liver
of Type 1 AIP. In the pancreas of Type 1 AIP, the ratio
of Foxp3-positive cells to inﬁltrated mononuclear cells
(Foxp3/Mono) was signiﬁcantly higher than in patients with
alcoholic chronic pancreatitis. In Type 1 AIP, Foxp3/Mono
and IgG4/Mono were positively correlated. This data is
similar to ﬂow cytometric analysis.
We compared the laboratory and immunohistochemical
ﬁndings of the liver biopsy specimens in the patients with
IgG4-SC and primary sclerosing cholangitis (PSC). After
stainingthesespecimenswithanti-IgG1,anti-IgG4,andanti-
Foxp3 antibodies, we compared the ratio of IgG4-, IgG1-,
and Foxp3-positive cells to inﬁltrated mononuclear cells
(IgG4, IgG1, Foxp3/Mono) among specimens. The ratio of
IgG4/G1-positive plasma cells was signiﬁcantly higher in
IgG4-SC than in PSC. The Foxp3/Mono ratio in patients
with IgG4-SC was signiﬁcantly increased compared with
PSC. In the patients with IgG4-SC, Foxp3-positive cells were
signiﬁcantly correlated with IgG4-positive cells. In the other
groups, there was no correlation [44].
7. AnimalModels of Type1 AIP
Wepreviouslyreportedseveralautoantibodiesinthepatients
with Type 1 AIP. Among the 26 patients with Type 1
AIP, antilactoferrin (LF) was detected in the sera of 19
(73.1%), antinuclear antibody (ANA) in 18 (69.2%), anti-
carbonic anhydrase (CA)-II in 14 (53.8%), RF in 6 (23.1%),
antismooth muscle antibody in 4 (15.4%), antiglutamic
acid decarboxylase antibody in 1 (3.8%), and antiislet cell
antibody in 1 (3.8%). However, AMA was not found in the
sera of any of these patients [45]. We hypothesized that LF
or CA-II may be one of the candidates of target antigen
in Type 1 AIP. We established animal models using LF or
CA-II as antigen. In neonatal thymectomized (nTx)-BALB/c
mouse models immunized with CA-II or LF, CD4+ T cells,
rather than B cells, there are the predominant inﬁltrates in
pancreas and salivary gland, and around bile duct, which are
similar to human Type 1 AIP [46]. The results from these
animal models suggest that the depletion of thymus-derived
Tregs in the periphery [46] and major histocompatibility
complex (MHC) class II restricted autoreactive CD4+ Tc e l l s
that escape from positive selection in the thymus may be
of importance to the induction of target organs. In the
early stage of Type 1 AIP, these CD4+ Tc e l l sp r o b a b l y
induce proinﬂammatory reactions as direct cytotoxic eﬀects
throughFasligand[47].IntheMHCclassII-deﬁcientmouse
[48] and in WBN/Kob rat models [49], CD8+ T cells may
play roles as eﬀector cells. WBN/Kob rats spontaneously
develop sialoadenitis, thyroiditis, sclerotic cholangitis, and
tubulointestinal nephritis because of congenitally decreased
peripheral Tregs. CD8+ T cells also seem to be eﬀector
cells in spite of unknown target antigens. WBN/Kob rats
showed deposition of tissue-speciﬁc IgG2b in the injured
pancreas and lachrymal glands [49]. Although details of the
IgG subclass in rodents remain unclear, rat IgG2b, a minor
subclass of IgG, is separated in a similar position to human
IgG4 by electrophoresis. In view of the results from animal
models, even though CD8+ Tc e l l sm a yb ep a r t i a l l yi n v o l v e d ,
CD4+ T cells play major roles in the development of systemic
inﬂammation, which are similar to the lesions in human
IgG4-related diseases [9, 50]. As TGF-β is an important
regulatory factor in maintaining immune homeostasis, TGF-
β-dominant negative mutant mice suggest that the loss of
TGF-β signaling may contribute to AIP [51].
8. Our Hypothesis for the Pathogenesis of
AIP asIgG4-RelatedDisease
Zen et al. reported that Th2 and regulatory cytokines,
and Tregs had an important role in IgG4-SC [52]. In the
patients with asthma, high-dose allergen exposure during
immunotherapy results in both immune deviation of Th2
responses in favor of a Th0/Th1 response and in the
generation of IL-10- and TGF-β-producing Tregs. Addition-
ally, these cytokines induce preferential switching of B-cell4 International Journal of Rheumatology
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Figure 1: Hypothesis for the pathogenesis of Type 1 autoimmune pancreatitis (AIP) in IgG4-related disease. In regard to central tolerance,
na¨ ıve and natural regulatory T cells (Tregs) derived from the thymus suppress autoreactive CD4 or CD8 cells in the normal state. In IgG4-
related disease, the basic concept is a biphasic mechanism of “induction” and “progression”. Initial response to self-antigens (e.g., lactoferrin
(LF), carbonic anhydrase II (CA-II), CA-IV, pancreatic secretory trypsin inhibitor (PSTI), amylase-alpha, and plasminogen binding protein
(PBP)peptideof Helicobacterpylori)mightbeinducedbydecreasedna¨ ıveTregs.Th2immuneresponsesarefollowedbyaTh1-typeimmune
response with the release of proinﬂammatory cytokines (interferon-γ (IFN-γ), interleukin (IL)-1β,I L - 2 ,t u m o rn e c r o s i sf a c t o r - α (TNF-
α)). Th2-type immune responses, producing IgG, IgG4, and autoantibodies may be involved in the pathophysiology of progression. The
production of IgG4 may be regulated by increased IL-10 secreted from inducible co-stimulatory molecule (ICOS)+ eﬀector Tregs. Fibrosis
may be regulated by TGF-β secreted from ICOS− Tregs. This ﬁgure modiﬁed from Okazaki et al. [54]. DC: dendritic cell, TE: eﬀector T cell,
nTreg: natural Tregs.
responses in favor of IgG and IgG4 antibodies [53]. We
proposed a hypothesis for the pathogenesis of Type 1 AIP
(Figure 1). This concept is based on a biphasic mechanism
of “induction” and “progression.” An initial response to
self-antigens (e.g., LF, CA-II, CA-IV, pancreatic secretory
trypsin inhibitor (PSTI), amylase-alpha, and plasminogen
binding protein (PBP) peptide of Helicobacter pylori)m i g h t
be induced by decreased na¨ ıve Tregs.
Decreased naive Tregs may be pathogenetic. In the early
stage of Type 1 AIP, proinﬂammatory cytokines (IFN-γ,
IL-1-β,I L - 2 ,T N F - α) are released via Th1-type immune
response.Inthechronicstage,IgG,IgG4,andautoantibodies
are produced via Th2-type immune responses. Particularly,
increased numbers of ICOS+ Tregs may aﬀect IgG4 produc-
tion via IL-10 in Type 1 AIP. On the other hand, ﬁbrosis may
be regulated by TGF-β secreted from ICOS− Tregs.
9. Conclusion
In conclusion, Tregs seem to be important in the production
ofIgG4aswellastheinductionofIgG4-relateddisease.How-
ever, further studies are necessary to clarify the pathogenesis,
includinggeneticbackgrounds,disease-speciﬁcantigens,and
the role of IgG4.International Journal of Rheumatology 5
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